High cure rate for Boehringer HCV drug
June 11, 2013Research and Development, Sales and Marketing Boehringer Ingelheim, HCV
One of Boehringer Ingelheim’s pipeline drugs has achieved high response rates in patients with chronic genotype-1 hepatitis C virus (HCV) in …
AstraZeneca to pay up to $1.2 billion for Pearl
June 10, 2013Research and Development, Sales and Marketing AstraZeneca, COPD, pearl therapeutics
AstraZeneca is betting big on lung disease specialist Pearl Therapeutics as it looks to spend $1.2 billion to acquire the …
Manufacturing news in brief
June 10, 2013Manufacturing and Production Biological E Ltd, Hospira and Sotax Group, Schott Pharmaceutical Systems, Valneva SE
A round-up of recent developments in the pharma manufacturing sector, including facility updates from Valneva, Schott and Hospira, plus Sotax’s …
Department of Health prioritises Francis response
June 7, 2013Sales and Marketing DH, Francis, Mid Staffs, NHS
The Department of Health has set out its priorities for the next year, explaining how it will enhance public health …
Working Life, Vifor Pharma, Derek Williams
June 7, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Vifor pharma, Working Life, williams
How did you find your way into your current role? I began my career in the UK as a sales …
NICE thumbs-up for Abilify
June 7, 2013Sales and Marketing Abilify, BMS, NICE, Otsuka
Adolescents who suffer from bipolar disorder should be treated on the NHS with Otsuka Pharmaceuticals’ Abilify, according to draft guidance …
Lilly UK sponsors ‘Go Dad Run’ charity
June 6, 2013Medical Communications go dad run, lilly, prostate
Lilly is sponsoring Olympic hurdler Colin Jackson’s ‘Go Dad Run’, a new 5k run for men to raise awareness of …
Internal buy-in is greatest barrier to social media
June 6, 2013Medical Communications Weber shandwick, digital, social media
Internal challenges – and not regulatory ones – are the biggest barriers to better use of social media in pharma, …
Boehringer unveils biopharma plant plan for China
June 6, 2013Manufacturing and Production Boehringer Ingelheim, China
Boehringer Ingelheim has said it intends to construct a cell-culture biopharmaceutical production facility in China offering contract R&D and manufacturing …
Novartis receives FDA warning
June 6, 2013Manufacturing and Production, Sales and Marketing CGMP, FDA, GMP, Novartis
The FDA has castigated Novartis for what it calls ‘significant violations’ of current good manufacturing practice (CGMP) regulations for finished …
PAN makes series of appointments and promotions
June 6, 2013Medical Communications Pan, agency, comms
Creative comms agency PAN has bolstered its team with two new arrivals and three promotions. Vanessa Hume has joined the …
Mirna appoints ex-Pfizer senior director
June 6, 2013Manufacturing and Production, Research and Development, Sales and Marketing Pfizer, miRNA
Biotech firm Mirna Therapeutics has appointed Dr Sinil Kim as vice president of Oncology and chief medical officer. Kim will …
Bayer takes over Conceptus
June 6, 2013Sales and Marketing Bayer, Conceptus
The Bayer Group, which contains Bayer HealthCare, has taken over US contraception specialist Conceptus in a $1.1 billion deal. The …
Aveo to cut workforce after FDA knock-back
June 6, 2013Research and Development, Sales and Marketing Aveo, FDA, cuts, tivozanib
Aveo will make major jobs cuts this year after news that a kidney cancer licence for its oncology drug tivozanib …
J&J recalls 32 million contraceptive packs
June 5, 2013Manufacturing and Production Cilest, J&J, JJ, recall
Johnson & Johnson has announced a 43-country recall of its oral contraceptive Cilest and suspended production of the drug because …
Novartis drug shows cancer promise
June 5, 2013Research and Development, Sales and Marketing ASCO, Cancer, Novartis
A Novartis drug which has been given breakthrough therapy designation by the FDA has demonstrated early promise in patients with …
Celgene predicts trio of blockbusters
June 5, 2013Sales and Marketing Celgene, Pomalidomide, Revlamid, Velcade
Europe’s medicines committee the CHMP has just adopted a positive opinion for Celgene’s new multiple myeloma treatment Pomalidomide Celgene (pomalidomide). …
HAVAS LYNX makes several leadership changes
June 5, 2013Medical Communications, Sales and Marketing Creative Lynx, HAVAS LYNX, PM Society Digital Awards
Comms agency HAVAS LYNX has realigned its senior team making a number of changes for the global firm as it …
GSK licences RA drug
June 5, 2013Research and Development, Sales and Marketing GSK, RA, morphosys
GlaxoSmithKline is gambling millions of euros on an investigational drug in a bid to get an edge in the fight …
AstraZeneca abandons late-stage RA drug
June 5, 2013Research and Development, Sales and Marketing AstraZeneca, RA, Rigel
AstraZeneca is to exit development of a new rheumatoid arthritis drug, after Phase III trials produced disappointing results.The Anglo-Swedish firm …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
